



Article

Comparison of the Efficacy of 35 Anticancer Drugs According to Genomic Profiling and Biological Characteristics of 14 Gastric Cancer Cell Lines

Sung-Hwa Sohn ¹, Hee Jung Sul ¹, Bum Jun Kim ²  and Dae Young Zang ^{1,2,*}

¹ Hallym Translational Research Institute, Hallym University Sacred Heart Hospital, Anyang-si 14066, Republic of Korea; iisupy@korea.ac.kr (S.-H.S.); glwjd82@naver.com (H.J.S.)

² Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Anyang-si 14068, Republic of Korea; getwisdom1025@gmail.com

* Correspondence: fhdzang@hallym.or.kr; Tel.: +82-31-380-4167

Abstract

Several receptors have received considerable attention as therapeutic targets in gastric cancer (GC), and numerous receptor inhibitors have been developed. However, the development of novel gastric cancer therapeutics is time-consuming. Therefore, this study aimed to identify drugs effective against gastric cancer from existing anticancer agents originally developed for other malignancies. In this study, the cancer-related genomic profiles of 286 genes were analyzed in 14 gastric cancer cell lines using targeted DNA sequencing, and these cell lines were utilized as models to evaluate the efficacy of 35 anticancer drugs. The 14 cell lines were assessed for 286 gene alterations, copy number variations, amplification of 14 gastric cancer-related therapeutic targets, and sensitivity to 35 drugs. p-MET and MET were overexpressed in the SNU5, SNU620, MKN45, and Hs746T cell lines, while p-EGFR was overexpressed in the NCI-N87 cell line. FGFR2 overexpression was observed in the Kato III and SNU16 cell lines. TGF β R1 was overexpressed in the MKN7 cell line. HER2 and CDK12 were overexpressed in the NCI-N87 and MKN7 cell lines. PD-L1 overexpression was detected in the Hs746T and MKN7 cell lines. CD44 was overexpressed in the SNU5 and Hs746T cell lines and CLDN18 overexpression was observed in the MKN7 cell line. Well-characterized gastric cancer cell lines are essential for drug development research. This study provides a framework for selecting cell lines that are responsive to each of the 35 anticancer drugs and elucidating their underlying therapeutic mechanisms through follow-up studies. Ultimately, clinical studies are required to confirm the therapeutic efficacy of the selected drugs.

Keywords: targeted therapy; gastric cancer; biomarker; cell line



Academic Editor: Peter J. K. Kuppen

Received: 29 January 2026

Revised: 17 February 2026

Accepted: 24 February 2026

Published: 25 February 2026

Copyright: © 2026 by the authors.

Licensee MDPI, Basel, Switzerland.

This article is an open access article distributed under the terms and

conditions of the [Creative Commons Attribution \(CC BY\)](https://creativecommons.org/licenses/by/4.0/) license.

1. Introduction

Gastric cancer (GC) is the fourth most common cancer worldwide in terms of both incidence and mortality, with the highest incidence rates observed in Eastern Asia [1,2]. Despite advances in chemotherapy, the prognosis for unresectable GC/gastroesophageal junction cancer remains poor, with a 5-year relative survival rate of less than 10% among patients with advanced disease (Cancer Stat Facts: Stomach cancer. National Cancer Institute [2025], <https://seer.cancer.gov/statistics-network/explorer/> (accessed on 3 November 2025)). Therefore, additional treatment strategies are urgently needed to improve clinical outcomes.

Drug discovery typically requires 10–15 years to develop a new therapeutic agent; however, the overall success rate is only approximately 2.01% [3]. To address this limitation, drug repositioning has recently been widely explored. Unlike traditional drug development approaches, drug repositioning, defined as identifying new therapeutic uses for existing drugs, represents an efficient strategy for discovering novel indications for approved agents. This approach enables a more rapid route to drug development because the clinical safety profiles and pharmacokinetic data of existing drugs have already been established [4]. Recent advances in genomics have further enabled the elucidation of disease-specific molecular mechanisms at a personalized level. Precision medicine has therefore become increasingly important in the management of GC. In many cases, clinically relevant molecular targets for which approved drugs already exist can be identified, creating opportunities for drug repurposing. Moreover, identifying therapeutic agents that target specific molecular alterations may shorten the time required to initiate effective treatment for individual patients.

Receptor tyrosine kinases (RTKs) and other receptors have been extensively investigated in GC. Among RTKs, amplification of the mesenchymal-epithelial transition factor proto-oncogene (MET), fibroblast growth factor receptor 2 (FGFR2), epidermal growth factor receptor (EGFR/ERBB1/HER1), and HER2 genes has been identified in approximately 2–24%, 2–9%, 27–64%, and 7–17% of patients with GC, respectively [5–8]. Upon activation, aberrant MET, FGFR2, EGFR, and HER2 signaling initiates complex intracellular cascades that promote cancer cell proliferation and migration, inhibition of apoptosis, and angiogenesis through the upregulation of vascular endothelial growth factor (VEGF) [9–13]. With recent improvements in the efficacy of targeted therapies, comprehensive tumor profiling, including the analysis of somatic mutations and copy-number variations (CNVs), has become increasingly necessary [14,15]. In particular, high-level CNVs play a critical role in tumorigenesis across multiple cancer types [15,16]. Cell line models with target gene overexpression have consistently demonstrated concordance with clinical responses, showing susceptibility to inhibitors directed against the corresponding molecular targets.

This study aimed to identify drugs that could serve as novel targeted therapies for GC through a drug repositioning approach using clinically approved agents. To this end, we identified therapeutic targets in 14 GC cell lines (14 gastric cancer cell lines expected to overexpress FGFR, HER2, FGFR2, MET, CDK12, PDL1, CD44, and CLDN18, which are of clinical interest, were used in this experiment) and evaluated the effects of 35 candidate drugs on cell viability.

2. Results

2.1. Characteristics of 14 GC Cell Lines

Fourteen GC cell lines (SNU16, SNU5, AGS, SNU719, MKN45, SNU1, N87, MKN74, MKN28, Kato III, MKN7, SNU638, SNU620, and Hs746T) were analyzed using targeted sequencing performed at the Theragen Bio Institute (Seongnam, Republic of Korea). The 286 GC panel genes and their individual genetic aberrations are presented in Figure 1.

To evaluate amplification of the 286 cancer-related genes in the 14 GC cell lines, CNV analysis was performed using targeted DNA sequencing data (Figure 2, Table S1). FGFR2 amplification, defined as a copy number greater than 20, was identified in 2/14 (14.3%) cell lines (Figure 2). MET amplification was observed in 4/14 (28.6%) cell lines, MYC amplification in 1/14 (7.1%), CDK12 amplification in 2/14 (14.3%), and ERBB2 (HER2) amplification in 2/14 (14.3%) cell lines.




Figure 1. Gene mutations in human gastric cancer cell lines measured by targeted next-generation sequencing.




Figure 2. Analysis of genes with CNVs of three or higher in at least six of the 14 gastric cancer cell lines, as determined by targeted next-generation sequencing.

2.2. Patterns of RTKs and GC-Related Targets in the 14 GC Cell Lines

Additional information on the 14 GC cell lines, including concomitant overexpression of RTKs or GC-related targets, is presented in Figures 3 and 4. Among the RTKs and GC-related targets, overexpression of MET, FGFR2, MYC, and CD44 was predominantly observed in diffuse-type GC cells, whereas overexpression of HER2, CDK12, TGFβR1, and CLDN18 was mainly observed in intestinal-type GC cells. We also found a statistically significant positive correlation between the expression of protein and CNV ($p < 0.0001$).




Figure 3. Cont.




Figure 3. Major protein expression profiles related to RTKs and cancer therapeutic targets in the 14 gastric cancer cell lines. Image J (<https://imagej.net/ij> (accessed on 3 November 2025)) was used for Western blot intensity analysis. Data are presented as mean $\pm$ standard deviation of each group ($n = 3$).

Lauren classification	Cell line	MSI state	Growth pattern	Sex	EBV	MET	HER2	FGFR2	MYC	CDK12	TGFβR1	CD44	CLDN18	PD-L1
						WB	≥20	WB	≥20	WB	≥20	WB	WB	WB
Diffuse type	SNU620	Unknown	suspension											
	SNU16	MSS	suspension											
	SNU5	MSS	suspension											
	MKN45	MSS	adherent											
	HS746T	MSS	monolayer											
	SNU638	Unknown	monolayer											
Intestinal type	KATOIII	MSS	mixed, adherent and suspension											
	AGS	MSS	monolayer											
	MKN28	MSS	monolayer											
	NCI-N87	MSS	monolayer											
	MKN74	Unknown	monolayer											
	MKN7	MSS	monolayer											
	SNU1	MSI-H	suspension											
	SNU719	Unknown	monolayer											

MSS: microsatellite stable
MSI: microsatellite instability
EBV : Epstein -Barr virus
≥20: CNVs of 20 or more
WB (western blotting): overexpression

negative
positive
Sex: female
Sex: male




Figure 4. Clinicopathological and biological characteristics of the 14 gastric cancer cell lines according to cancer therapeutic targets, including CNVs or protein overexpression. Lauren classification was compared with other biomarkers using targeted DNA sequencing or Western blot analysis. Correlation between CNV and WB protein expression intensity in 14 GC cells. $R = 0.7581$ (c-MET) or 0.9052 (FGFR2), $p < 0.0001$ (Spearman correlation).

2.3. Sensitivity of 35 Drugs in the 14 GC Cell Lines

We conducted a screening experiment using 1443 FDA-approved drugs in the SNU620 gastric cancer cell line. Among these, we initially selected drugs that reduced the viability of the SNU620 cell line by 60% or less. Among these, we further screened for drugs that are currently used in clinical practice (drugs used in gastric cancer treatment were excluded, Supplementary File S1). To evaluate drug repositioning potential in the 14 GC cell lines, sensitivity to 35 drugs was assessed (Figure 5). Drug sensitivity was analyzed based on the viability rate (%) in the 14 GC cell lines. Among these cell lines, the drugs that reduced cell viability to 50% or less in more than 7 cell lines were epirubicin, doxorubicin, topotecan HCl, ponatinib, mitoxantrone 2HCl, fostamatinib, fedratinib, daunorubicin, ceritinib, and mitomycin C.




Figure 5. Cont.




Figure 5. Cont.




Figure 5. Sensitivity of the 35 drugs tested in the 14 gastric cancer cell lines. Inhibition rate (%) of each drug at a concentration of 10 μ M is presented.

3. Discussion

Traditional GC drug development requires a significant amount of time, typically 10–15 years [17]. In contrast, drug repurposing involves the identification of existing drugs for new indications, different from their original purpose. By leveraging drugs with established safety and efficacy profiles, the need to discover entirely new candidates is eliminated, thereby shortening the safety and efficacy evaluation period and markedly

reducing the time and cost associated with new drug development [4,18]. Accordingly, we aimed to identify effective therapeutic agents for GC among existing anticancer drugs developed for other malignancies. In addition, appropriate preclinical studies, particularly those using patient-derived cancer cell lines, are critically important for successful drug development. In this study, we analyzed 286 genetic alterations and CNVs in 14 GC cell lines using targeted DNA sequencing to identify potential GC therapeutic targets for each cell type and evaluated drug sensitivity to 35 agents in these cell lines.

Among RTKs and non-RTKs, MET, EGFR, HER2, VEGFR, and FGFR2 as well as TGF β R1, CDK12, PD-L1, CD44, and CLDN18 are currently being considered as potential targets for GC treatment, respectively [19–22]. RTKs catalyze the transfer of phosphate groups from ATP to tyrosine residues on intracellular proteins, thereby transducing extracellular signals into the cell, whereas non-RTKs act primarily on intracellular signaling pathways [23,24]. In particular, upregulation of RTKs has been frequently observed in GC, suggesting that RTK inhibitors may play an important role in its treatment. Drugs that reduced the viability of p-MET- and MET-overexpressing SNU5, SNU620, MKN45, and Hs746T cell lines by approximately 25% included methotrexate, topotecan HCl, fostamatinib, and mitomycin C. Ponatinib and mitomycin C reduced the viability of FGFR2-overexpressing Kato III and SNU16 cell lines by more than 50%. In the p-EGFR-overexpressing NCI-N87 cell line, lapatinib and mitomycin C reduced cell viability by more than 50%. Afatinib, afatinib dimaleate, alpelisib, azacitidine, lapatinib ditosylate, daunorubicin, and fostamatinib reduced the viability of HER2-overexpressing NCI-N87 and MKN7 cell lines by more than 25%.

Non-RTK targets also play important roles in GC. Among the 14 GC cell lines, MKN7, MKN28, MKN74, N87, SNU16, and SNU620 harbored mutations in CDK12; however, only MKN7 and N87 exhibited CDK12 overexpression. CDK12 promotes angiogenesis in GC by activating the PI3K/AKT/mTOR signaling pathway [25]. Afatinib, afatinib dimaleate, alpelisib, azacitidine, lapatinib ditosylate, daunorubicin, and fostamatinib reduced the viability of CDK12-overexpressing NCI-N87 and MKN7 cell lines by more than 25%. In advanced cancers, TGFBR2 promotes tumor progression, further emphasizing its importance as a potential therapeutic target [26,27]. In addition, isoform 2 of CLDN18 (CLDN18.2) is expressed exclusively in differentiated epithelial cells of the gastric mucosa and primary GC, highlighting its potential as a therapeutic target [28]. Topotecan HCl, ceritinib, and afatinib dimaleate reduced the viability of the MKN7 cell line, which overexpressed TGF β R1 and CLDN18, by more than 50%. PD-L1 is expressed in GC and is significantly more prevalent in males, HER2/neu-positive tumors, proximal GC, unclassified and papillary GC, MSI (define) GC, and EBV-associated GC [29]. Afatinib dimaleate and topotecan HCl reduced viability by more than 50% in PD-L1-overexpressing Hs746T and MKN7 cell lines. High CD44 expression in GC has been associated with increased recurrence and metastasis rates and poor prognosis [30,31]. Afatinib, doxorubicin, daunorubicin, mitoxantrone 2HCl, epirubicin, topotecan HCl, and mitomycin C reduced the viability of CD44-overexpressing Hs746T and SNU5 cell lines by more than 50%.

4. Materials and Methods

4.1. Reagents

Axitinib, afatinib, lapatinib ditosylate, tozasertib, barasertib, doxorubicin HCl, fluorouracil, methotrexate, epirubicin HCl, etoposide, topotecan HCl, vincristine sulfate, rigosertib, ponatinib, mycophenolate mofetil, azacitidine, simvastatin, lapatinib, mitoxantrone 2HCl, mycophenolic acid, fostamatinib, fedratinib, lonafarnib, alpelisib, daunorubicin HCl, vinorelbine tartrate, vinblastine sulfate, binimetinib, ceritinib, afatinib dimaleate,

palbociclib HCl, gemcitabine HCl, palbociclib isethionate, venetoclax, and mitomycin C were obtained from Selleck Chemicals (Houston, TX, USA).

4.2. Cell Lines and Cell Culture

The GC cell lines SNU16, SNU5, AGS, SNU719, MKN45, SNU1, N87, MKN74, MKN28, Kato III, MKN7, SNU638, SNU620, and Hs746T were obtained from the Korean Cell Line Bank (Seoul, Republic of Korea). All cell lines except Hs746T were cultured in RPMI 1640 medium (Thermo Fisher Scientific, Waltham, MA, USA), while Hs746T cells were maintained in Dulbecco's Modified Eagle Medium (Thermo Fisher Scientific). Both media were supplemented with 10% (*v/v*) fetal bovine serum and 1% (*w/v*) penicillin/streptomycin. All cells were cultured under standard conditions.

4.3. Target DNA-Sequencing Analysis

The target DNA-sequencing methodology has been described in detail previously [32]. Fourteen GC cell lines were subjected to target DNA-sequencing analysis. The 1000 Genomes data were used to filter out common germline variants that are not pathogenic. Genes exhibiting low and modified SnpEff impact figures were removed. We selected genes that met the GATK Mutect2 Variant Calling filter PASS criteria, i.e., those with high SnpEff impact values.

4.4. Cell Viability Assay

To evaluate the effects of 35 drugs on cell viability, an MTS (define) assay was performed using the CellTiter 96 Aqueous One Solution Cell Proliferation Assay kit (Promega, Madison, WI, USA). Briefly, 14 GC cell lines were seeded into 96-well plates at approximately 50% confluence and incubated for 24 h. The cells were subsequently treated with the indicated drugs at a concentration of 10 μ M for 48 h. Cell viability was then assessed using the MTS assay according to the manufacturer's instructions.

4.5. Western Blotting

Western blotting was performed using standard procedures. The primary antibodies used were anti-MET (#4560; 1:1000; Cell Signaling Technology [CST], Danvers, MA, USA), anti-phospho-MET (#3077; 1:1000; CST), anti-TGF β R1 (sc518018; 1:1000; Santa Cruz Biotechnology, Dallas, TX, USA), anti-phospho-EGFR (#2234; 1:1000; CST), anti-EGFR (ab32077; 1:1000; Abcam, Cambridge, UK), anti-CD44 (#3570; 1:1000; CST), anti-c-MYC (sc40; 1:1000; Santa Cruz Biotechnology, Dallas, TX, USA), anti-FGFR2 (ab10648; 1:1000; Abcam), anti-Frizzled 5 (ab75234; 1:1000; Abcam), anti-CLDN18 (#38-800; 1:1000; Invitrogen), anti-HER2 (#2165; 1:1000; CST), anti-CDK12 (ab317746; 1:1000; Abcam), anti-VEGFR2 (#9698; 1:1000; CST), anti-PD-L1 (#13684; 1:1000; CST), and anti-GAPDH (sc32233; 1:4000; Santa Cruz Biotechnology).

4.6. Correlation Analysis

The data were correlation-analyzed using GraphPad Prism 5 software (GraphPad Software Inc., La Jolla, CA, USA). All values are presented as mean $\pm$ S.D. Statistical significance was examined using the Spearman correlation test. A *p* value <0.05 was considered to indicate statistical significance.

5. Conclusions

This study identified GC cell lines that are responsive to each of the 35 tested drugs and provided a basis for elucidating their underlying therapeutic mechanisms through subsequent follow-up studies. Ultimately, in vivo validation and clinical trials will be required to confirm the therapeutic efficacy of the selected drugs.

Supplementary Materials: The following supporting information can be downloaded at <https://www.mdpi.com/article/10.3390/ijms27052133/s1>.

Author Contributions: S.-H.S. performed some of the molecular experiments, analyzed the data, and drafted the article. H.J.S. performed the other molecular experiments. B.J.K. critically revised the manuscript in terms of important intellectual content. D.Y.Z. supervised the study, obtained funding, guided the data analyses, and edited the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Korea Health Technology R&D Project (grant number RS-2022-KH129464), the Patient-Centered Clinical Research Coordinating Center (PACEN, grant number RS-2020-KH095267) of the Ministry of Health and Welfare, and the Hallym University Research Fund. No funder played any role in the study design; data collection, analyses, or interpretation; manuscript preparation; or decision to publish the results.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The original contributions presented in this study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

Conflicts of Interest: The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:

GC	gastric cancer
GEJC	gastric ductal carcinoma in situ
RTKs	receptor tyrosine kinases
MET	mesenchymal–epithelial transition
FGFR2	fibroblast growth factor receptor 2
EGFR/ERBB1/HER1	epidermal growth factor receptor
CNV	copy number variations
CLDN18.2	isoform 2 of CLDN18

References

1. Jung, K.W.; Won, Y.J.; Kong, H.J.; Lee, E.S. The Community of Population-Based Regional Cancer Registries. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015. *Cancer Res. Treat.* **2018**, *50*, 303–316. [\[CrossRef\]](#)
2. Sitarz, R.; Skierucha, M.; Mielko, J.; Offerhaus, G.J.A.; Maciejewski, R.; Polkowski, W.P. Gastric cancer: Epidemiology, prevention, classification, and treatment. *Cancer Manag. Res.* **2018**, *10*, 239–248. [\[CrossRef\]](#)
3. Yeu, Y.; Yoon, Y.; Park, S. Protein localization vector propagation: A method for improving the accuracy of drug repositioning. *Mol. Biosyst.* **2015**, *11*, 2096–2102. [\[CrossRef\]](#)
4. Xue, H.; Li, J.; Xie, H.; Wang, Y. Review of Drug Repositioning Approaches and Resources. *Int. J. Biol. Sci.* **2018**, *14*, 1232–1244. [\[CrossRef\]](#)
5. Maroun, C.R.; Rowlands, T. The Met receptor tyrosine kinase: A key player in oncogenesis and drug resistance. *Pharmacol. Ther.* **2014**, *142*, 316–338. [\[CrossRef\]](#)
6. Matsumoto, K.; Arao, T.; Hamaguchi, T.; Shimada, Y.; Kato, K.; Oda, I.; Taniguchi, H.; Koizumi, F.; Yanagihara, K.; Sasaki, H.; et al. FGFR2 gene amplification and clinicopathological features in gastric cancer. *Br. J. Cancer* **2012**, *106*, 727–732. [\[CrossRef\]](#)
7. Arienti, C.; Pignatta, S.; Tesi, A. Epidermal Growth Factor Receptor Family and its Role in Gastric Cancer. *Front. Oncol.* **2019**, *9*, 1308. [\[CrossRef\]](#)
8. Tanner, M.; Hollmen, M.; Junttila, T.T.; Kapanen, A.I.; Tammola, S.; Soini, Y.; Helin, H.; Salo, J.; Joensuu, H.; Sihvo, E.; et al. Amplification of HER-2 in gastric carcinoma: Association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. *Ann. Oncol.* **2005**, *16*, 273–278. [\[CrossRef\]](#)
9. Lang, S.A.; Klein, D.; Moser, C.; Gaumann, A.; Glockzin, G.; Dahlke, M.H.; Dietmaier, W.; Bolder, U.; Schlitt, H.J.; Geissler, E.K.; et al. Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. *Mol. Cancer Ther.* **2007**, *6*, 1123–1132. [\[CrossRef\]](#)

10. Sohn, S.H.; Sul, H.J.; Kim, B.J.; Zang, D.Y. Responses to the Tepotinib in Gastric Cancers with MET Amplification or MET Exon 14 Skipping Mutations and High Expression of Both PD-L1 and CD44. *Cancers* **2022**, *14*, 3444. [\[CrossRef\]](#)
11. Kawakami, H.; Okamoto, I.; Arao, T.; Okamoto, W.; Matsumoto, K.; Taniguchi, H.; Kuwata, K.; Yamaguchi, H.; Nishio, K.; Nakagawa, K.; et al. MET amplification as a potential therapeutic target in gastric cancer. *Oncotarget* **2013**, *4*, 9–17. [\[CrossRef\]](#)
12. Turner, N.; Grose, R. Fibroblast growth factor signalling: From development to cancer. *Nat. Rev. Cancer* **2010**, *10*, 116–129. [\[CrossRef\]](#)
13. Moasser, M.M. The oncogene HER2: Its signaling and transforming functions and its role in human cancer pathogenesis. *Oncogene* **2007**, *26*, 6469–6487. [\[CrossRef\]](#)
14. Wang, Y.; Yao, X.; Li, S.N.; Suo, A.L.; Tian, T.; Ruan, Z.P.; Guo, H.; Yao, Y. Detection of prostate cancer related copy number variations with SNP genotyping array. *Eur. Rev. Med. Pharmacol. Sci.* **2013**, *17*, 2916–2922.
15. Shlien, A.; Malkin, D. Copy number variations and cancer. *Genome Med.* **2009**, *1*, 62. [\[CrossRef\]](#)
16. Xu, H.; Zhu, X.; Xu, Z.; Hu, Y.; Bo, S.; Xing, T.; Zhu, K. Non-invasive Analysis of Genomic Copy Number Variation in Patients with Hepatocellular Carcinoma by Next Generation DNA Sequencing. *J. Cancer* **2015**, *6*, 247–253. [\[CrossRef\]](#)
17. Sertkaya, A.; Beleche, T.; Jessup, A.; Sommers, B.D. Costs of Drug Development and Research and Development Intensity in the US, 2000–2018. *JAMA Netw. Open* **2024**, *7*, e2415445. [\[CrossRef\]](#)
18. Jourdan, J.P.; Bureau, R.; Rochais, C.; Dallemagne, P. Drug repositioning: A brief overview. *J. Pharm. Pharmacol.* **2020**, *72*, 1145–1151. [\[CrossRef\]](#)
19. Panahizadeh, R.; Panahi, P.; Asghariazar, V.; Makaremi, S.; Noorkhajavi, G.; Safarzadeh, E. A literature review of recent advances in gastric cancer treatment: Exploring the cross-talk between targeted therapies. *Cancer Cell Int.* **2025**, *25*, 23. [\[CrossRef\]](#)
20. Becker, J.C.; Muller-Tidow, C.; Serve, H.; Domschke, W.; Pohle, T. Role of receptor tyrosine kinases in gastric cancer: New targets for a selective therapy. *World J. Gastroenterol.* **2006**, *12*, 3297–3305. [\[CrossRef\]](#)
21. Hashimoto, I.; Oshima, T. Claudins and Gastric Cancer: An Overview. *Cancers* **2022**, *14*, 290. [\[CrossRef\]](#) [\[PubMed\]](#)
22. Agnarelli, A.; Vella, V.; Samuels, M.; Papanastasopoulos, P.; Giamas, G. Incorporating Immunotherapy in the Management of Gastric Cancer: Molecular and Clinical Implications. *Cancers* **2022**, *14*, 4378. [\[CrossRef\]](#) [\[PubMed\]](#)
23. Qin, S.; Li, A.; Yi, M.; Yu, S.; Zhang, M.; Wu, K. Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. *J. Hematol. Oncol.* **2019**, *12*, 27. [\[CrossRef\]](#)
24. Zhong, L.; Li, Y.; Xiong, L.; Wang, W.; Wu, M.; Yuan, T.; Yang, W.; Tian, C.; Miao, Z.; Wang, T.; et al. Small molecules in targeted cancer therapy: Advances, challenges, and future perspectives. *Signal Transduct. Target. Ther.* **2021**, *6*, 201. [\[CrossRef\]](#)
25. Gao, L.Z.; Wang, J.Q.; Chen, J.L.; Zhang, X.L.; Zhang, M.M.; Wang, S.L.; Zhao, C. CDK12 Promotes the Proliferation, Migration, and Angiogenesis of Gastric Carcinoma via Activating the PI3K/AKT/mTOR Signaling Pathway. *Appl. Biochem. Biotechnol.* **2023**, *195*, 6913–6926. [\[CrossRef\]](#) [\[PubMed\]](#)
26. Ikushima, H.; Miyazono, K. TGFbeta signalling: A complex web in cancer progression. *Nat. Rev. Cancer* **2010**, *10*, 415–424. [\[CrossRef\]](#)
27. Jin, Z.; Huang, Z.; Wu, C.; Zhang, F.; Gao, Y.; Guo, S.; Tao, X.; Lu, S.; Zhang, J.; Huang, J.; et al. Molecular insights into gastric cancer: The impact of TGFBR2 and hsa-mir-107 revealed by microarray sequencing and bioinformatics. *Comput. Biol. Med.* **2024**, *172*, 108221. [\[CrossRef\]](#)
28. Sahin, U.; Koslowski, M.; Dhaene, K.; Usener, D.; Brandenburg, G.; Seitz, G.; Huber, C.; Tureci, O. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. *Clin. Cancer Res.* **2008**, *14*, 7624–7634. [\[CrossRef\]](#)
29. Boger, C.; Behrens, H.M.; Mathiak, M.; Kruger, S.; Kalthoff, H.; Rocken, C. PD-L1 is an independent prognostic predictor in gastric cancer of Western patients. *Oncotarget* **2016**, *7*, 24269–24283. [\[CrossRef\]](#)
30. Jung, W.Y.; Kang, Y.; Lee, H.; Mok, Y.J.; Kim, H.K.; Kim, A.; Kim, B.H. Expression of moesin and CD44 is associated with poor prognosis in gastric adenocarcinoma. *Histopathology* **2013**, *63*, 474–481. [\[CrossRef\]](#)
31. Hou, W.; Kong, L.; Hou, Z.; Ji, H. CD44 is a prognostic biomarker and correlated with immune infiltrates in gastric cancer. *BMC Med. Genom.* **2022**, *15*, 225. [\[CrossRef\]](#) [\[PubMed\]](#)
32. Sohn, S.H.; Sul, H.J.; Kim, B.J.; Zang, D.Y. Comparison of Tepotinib, Paclitaxel, or Ramucirumab Efficacy According to the Copy Number or Phosphorylation Status of the MET Gene: Doublet Treatment versus Single Agent Treatment. *Int. J. Mol. Sci.* **2024**, *25*, 1769. [\[CrossRef\]](#) [\[PubMed\]](#)

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.